SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 156.28+0.5%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walkingshadow who wrote (1038)6/13/1999 1:09:00 AM
From: Vector1  Read Replies (2) of 1686
 
On the subject of pipelines the key issue is not number of candidates but likelihood of success and timing of approval and size of market. Amgen for example only has 2 approved products but they are both billion dollar drugs. In Biogen's case Avonex will likely become a billion dollar drug over the next three or four years and both Antova and Amevive have billion dollar potential. Indeed Amevive which is in Phase II trials for Lupus and Transplant rejection (among other indications)could be a multibillion blockbuster.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News